SVA
SINOVAC BIOTECH LTDBS score 19.6LOWPHASE4 · mkt cap $642.4M · rev ttm $0
drug hypothesis
Sabin Inactivated Poliovirus Vaccine (IPV) modulates Poliovirus (serotypes 1, 2, 3) to treat Prevention of poliomyelitis (polio).
moa:Induces humoral immunity through seroconversion (antibody production) against poliovirus serotypes following three-dose immunization regimen
score breakdown
trial design25
base rate disconnect4
language red flags40
composite19.6
valuation analysis
market cap$642.4M
revenue ttm$0
phasePHASE4
historical base rate80%
disconnect ratio0.2x
lead trialNCT02001233
meta
cik0001084201
first discovered2026-04-09
last updated2026-04-10
statusACTIVE
llm model—
extracted at2026-04-10
trial design
Phase 1, randomized, single-center, placebo-controlled study enrolling 708 participants to evaluate safety and immunogenicity of Sabin IPV
primary endpoint:Seroconversion rates (SCRs) after three-dose regimen at 90 days
claimed differentiation
Not applicable - no company or product-specific differentiation claims provided in trial data
language red flags
- Trial data only - no SEC filing or company claims provided to evaluate for red flags
- No differentiation claims, forward-looking statements, or risk factors present in provided data
company-stated risks
- Not provided in trial data - only standard safety monitoring through adverse event tracking listed as secondary endpoints